Ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate is a member of the 4-hydroxyquinoline-3-carboxylate family, a class of quinoline derivatives that has been studied for both agricultural and medicinal applications. The general 4-hydroxy-3-quinolinecarboxylate scaffold consists of a fused benzene–pyridine system bearing a hydroxy group at the 4-position and a carboxylate functionality at the 3-position; esterification of the carboxylate (for example, as an ethyl ester) provides an accessible synthetic handle for further derivatization. Halogenation on the aromatic ring, including bromination at the 6-position, is a common structural variation that alters electronic properties and enables cross-coupling and substitution chemistry for the rapid generation of analogues.
The discovery and early exploration of quinoline-3-carboxylates trace back several decades, when medicinal and agrochemical researchers synthesized series of alkyl and alkoxy-substituted 6,7-dialkoxy and related quinoline esters and evaluated them for anticoccidial activity. Structure–activity relationships established in these studies showed that substitution patterns on the benzene portion of the quinoline ring—particularly at the 6- and 7-positions—influenced potency against protozoan parasites. Alkoxy and halogen substituents modulated both lipophilicity and metabolic stability, and in multiple series the ethyl 4-hydroxyquinoline-3-carboxylate core emerged as a privileged framework for anticoccidial leads. Synthetic work from these early programs documented practical methods to prepare diversified 3-quinolinecarboxylate esters and to introduce 6- and 7-position substituents, providing a foundation for subsequent analogue development.
From a synthetic standpoint, the ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate motif is accessible by established quinoline-forming procedures followed by regioselective functional group manipulations. Typical laboratory sequences build the quinoline nucleus from an aniline or related precursor and a 1,3-dicarbonyl partner, then effect selective halogenation or halogen–metal exchange at the desired ring position. The ethyl ester can be carried through multi-step syntheses or selectively hydrolyzed to the corresponding acid for amide- or heterocycle-forming transformations. The phenolic 4-hydroxy group offers additional orthogonal chemistry—O-alkylation, O-acylation, or participation in intramolecular cyclizations—allowing chemists to convert the basic scaffold into a wide variety of fused or appended heterocycles.
Applications reported for the broader family of 4-hydroxyquinoline-3-carboxylates include anticoccidial agents and, more recently, development of bioactive quinoline carboxylic acids as inhibitors of human enzymes. Early agricultural studies identified ethyl 4-hydroxyquinoline-3-carboxylate derivatives with potent activity against Eimeria species, and optimization of substitution at positions 6 and 7 produced derivatives with enhanced in vivo efficacy. In medicinal chemistry, derivatives of quinoline-3-carboxylic acids have been investigated as enzyme inhibitors, where the carboxylate or its derivatives can engage key active-site residues and the fused heterocyclic core mimics privileged heteroaromatic pharmacophores. The combination of a halogen handle (for late-stage diversification), a modifiable ester group, and a hydrogen-bonding phenol makes ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate a practical intermediate in both agrochemical lead optimization and drug-discovery programs.
When used as a synthetic intermediate, careful attention to handling and storage is required: the phenolic and ester functionalities can be sensitive to strong acids or bases, and halogenated aromatics can undergo side reactions under harsh conditions. In development workflows, optimization often focuses on converting initial screening hits into crystalline, pharmaceutically acceptable forms, improving solubility and stability for formulation.
In summary, ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate sits within a well-established class of quinoline-based compounds that have proven utility for generating biologically active derivatives. The scaffold’s combination of a modifiable ester, a reactive hydroxy group, and a halogenated aromatic position supports broad synthetic elaboration, which historically has led to both anticoccidial agents and, in more recent studies, enzyme-targeted quinoline carboxylates applied in medicinal chemistry.
References
Spencer CF, Engle A, Yu CN, Finch RC, Watson EJ, Ebetino FF, Johnson CA (1966) Anticoccidial activity in a series of alkyl 6,7-dialkoxy-4-hydroxy-3-quinolinecarboxylates. Journal of Medicinal Chemistry 9(6) 934–936. DOI: 10.1021/jm00324a032
Mizzoni RH, Goble F, Szanto J, Maplesden DC, Brown JE, Boxer J, De Stevens G (1968) Ethyl 6,7-bis(cyclopropylmethoxy)-4-hydroxy-3-quinolinecarboxylate, a potent anticoccidial agent. Experientia 24(12) 1188–1189. DOI: 10.1007/BF02146611
Syniugin AR, Ostrynska OV, Chekanov MO, Volynets GP, Starosyla SA, Bdzhola VG, Yarmoluk SM (2016) Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2. Journal of Enzyme Inhibition and Medicinal Chemistry 31(sup4) 160–169. DOI: 10.1080/14756366.2016.1222584
|
GHS07 Warning Details
Discovory and Applicatios